Publication | Open Access

Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer

UrologyPhase Ii TrialMedicinePharmacologyPharmacotherapyAnti-cancer AgentCancer TreatmentProstatic DiseaseOncology